Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target
Dabin Liu(Institute of Microbiology), Jun Yu(Yueyang Second People's Hospital), Yunfei Zhou(Harbin Medical University), Chi Chun Wong(Chinese University of Hong Kong), Chuangen Li, Joseph J.�Y. Sung(Nanyang Technological University), Yanquan Zhang(University of Kentucky), Huarong Chen(Chinese University of Hong Kong), Bin Wu(Sun Yat-sen University), Weiqi Xu(Chinese University of Hong Kong), Yidong Yang(University of Science and Technology of China), Li Fu(Shenzhen University), Gong Cheng(Chinese University of Hong Kong), Liuyang Zhao(Shenzhen University), Nathalie Wong(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong)
Cited by 285
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
Neoantigens: promising targets for cancer therapy
|Signal Transduction and Targeted Therapy|2023|896
Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial
|The Lancet|2004|895
Screening for gastric cancer in Asia: current evidence and practice
|The Lancet Oncology|2008|830